1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Beijing Sun-Novo Pharmaceutical Research Co. Ltd. Class A

Beijing Sun-Novo Pharmaceutical Research Co. Ltd. Class A

SSSE:688621
56.00
CNY
-2.99
(-5.07%)
1.08EPS
52.16P/E
6.15BMarket Cap
Oct 30Next Earn
Beijing Sun-Novo Pharmaceutical Research Co. Ltd. Class A
SSE:688621
(Shanghai Stock Exchange)

Recent

price

56.00

P/E

ratio

52.16

div

yld

0.84%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.39
1.63
2.78
4.14
5.04
6.05
8.32
9.6
11.15
10.42
Revenue per Share
0.02
0.25
0.56
0.86
1.08
1.4
1.65
1.58
1.86
1.05
Basic EPS, GAAP
-0.14
0.33
0.37
0.43
0.03
- -
0.18
0.01
0.46
- -
Free Cash Flow per Basic Share
0.01
0.01
- -
0.01
0.01
0.24
0.5
0.34
0.29
0.47
Dividend per Share
0.41
0.9
1.39
2.25
6.8
8.01
9.29
9.83
10.87
10.73
Book Value per Share
0.39
0.63
1.1
1.89
6.54
7.74
9.01
9.55
10.64
10.49
Tangible Book Value per Share
92
83
84
84
98
112
112
112
110
111
Basic Weighted Avg Shares
36
135
234
347
494
677
932
1,078
1,222
1,152
Sales/Revenue/Turnover
6.28
21.08
22.72
24.76
27.31
28.06
27.68
21.72
26.49
22.03
Operating Margin (%)
2
5
8
10
28
40
45
50
52
- -
Depreciation Expense
2
21
47
72
106
156
185
177
204
116
Net Income, GAAP
0.1
13.4
11.98
9.87
10.9
6.17
5.43
3.96
- -
- -
Effective Tax Rate (%)
5.49
15.37
20.3
20.86
21.4
23.13
19.82
16.45
16.68
10.11
Profit Margin (%)
-2
-5
15
60
524
522
596
736
772
694
Working Capital
- -
- -
- -
31
50
34
41
102
78
70
LT Debt
33
74
119
193
770
909
1,057
1,103
1,233
1,216
Total Equity
- -
30.22
45.86
37.89
17.56
14.8
13.95
11.59
- -
- -
Return on Invested Capital (%)
- -
33.8
44.56
36.6
17.14
15.25
14.84
13.15
- -
- -
Return on Capital (%)
- -
37.89
49.41
47.4
22.22
18.86
19.08
16.58
17.59
10.43
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
536
544
613
LT Borrowings
48
38
38
LT Finance Leases
30
27
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
6,961
7,188
6,150

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,741
1,721
1,668
Cash, Cash Equivalents & STI
537
419
505
Accounts Receivable, Net
582
633
551
Inventories
14
15
13
Total Current Liabilities
969
962
974
Payables & Accruals
- -
- -
- -
ST Debt
536
544
613
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
69.91%
11.87%
Free Cash Flow
- -
4,895.69%
3,206.73%
Net Income, GAAP
- -
24.58%
14.91%
Sales/Revenue/Turnover
- -
29.19%
13.33%
Total Cash Common Dividend
- -
427.59%
-15.45%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
252
311
354
162
1,078
2025
231
359
- -
366
1,222
2026
197
229
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.66
0.68
0.53
-0.27
1.58
2025
0.27
0.92
- -
0.37
1.86
2026
0.18
-0.41
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.04
0.2
0.07
0.34
2025
0.03
0.2
- -
0.03
0.29
2026
0.03
0.22
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) provides comprehensive preclinical and integrated clinical research and development services to pharmaceutical companies, new drug research institutions, and biotechnology firms in China. Founded in 2009 and headquartered at Building 7, No. 79 Shuangying West Road, Science and Technology Park, Changping District, Beijing, the company operates primarily in the domestic market as a contract research organization (CRO). Its core services encompass drug discovery; pharmacology and pharmacodynamics studies; pharmacy research including raw drug preparation, structure confirmation, and dosage selection; clinical research covering medical, operational, data management, statistical analysis, risk management, and quality management services; bioanalysis via mass spectrometry, immunological, cell biology, and molecular biology platforms; and specialized platforms for external skin preparations, pediatric drugs, respiratory tract delivery, polypeptide drug design, genotoxic impurity detection, slow/controlled release preparations, and drug synthesis. The company also offers site management organization (SMO) services, pharmacovigilance, medical writing, TMF document management, quality control, and registration support for chemical drugs, biological products, and medical devices, with a focus on generic drugs, innovative drugs, consistency evaluations, and therapeutic areas such as analgesia, nephropathy, tumors, cardiovascular, and antimicrobials. In recent developments, the company reported 2024 revenue of 1.078 billion yuan, driven by 41% growth in its clinical trial and bioanalysis segment to 512 million yuan, alongside new orders of 1.786 billion yuan and a backlog of 3.273 billion yuan; increased R&D investment to 172 million yuan (15.94% of revenue) supporting over 430 projects including 89 self-developed ones; announced a 100 million yuan share buyback in December 2024; agreed in May 2025 to acquire Jiangsu Langyan Life Technology Holdings Co., Ltd.; and plans in November 2025 to divest its 70% stake in loss-making subsidiary Shanghai Measurable Data.